Subscribe To
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
— Initiating FHD-286 combination study in AML in the third quarter of 2023 — Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND — Cash, cash equivalents, and marketable securities of $284.3 million, as of June 30, 2023, provides cash runway into the second half of 2025 CAMBRIDGE, […] The post Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update appeared first on ForexTV...
Read More
Posted: Aug 4 2023, 11:00
Author Name: forextv
Views: 080771